Spectrum Pharmaceuticals has achieved complete enrollment for a Phase II trial of ozarelix in benign prostatic hypertrophy (BPH), more that four months ahead of schedule. The multicenter clinical trial is designed to evaluate both objective parameters, such as improvement in urine flow and shrinkage of the prostate volume, as well as various symptoms of BPH over a period of several months. The trial is being conducted in Europe with the collaboration of AEterna Zentaris.
Ozarelix is a fourth-generation LHRH (luteinizing hormone releasing hormone), also known as GnRH (gonadotropin releasing hormone), antagonist. LHRH antagonists have the potential to treat hormone-dependent cancers as well as benign proliferative disorders such as benign prostatic hypertrophy and endometriosis.